Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-09
2007-01-09
McKenzie, Thomas (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S359000, C514S424000, C514S676000, C549S074000, C548S546000
Reexamination Certificate
active
10496334
ABSTRACT:
The present invention relates to novel hydroxyethylene compounds having Asp2 (β-secretase. BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.
REFERENCES:
patent: WO 01/70672 (2001-09-01), None
Citron et. al., “Human Beta-Secretase and Alzheimer's Disease”, Expert Opinion Therapeutic Patents (2001) 5(3):341-346.
Jhee et. al., “B-Amyloid Therapies in Alzheimer's Disease”, Expert Opinion on Investigational Drugs (2001) 10(4):593-605.
Faller Andrew
Milner Peter Henry
Ward John Gerard
Deppenbrock Bonnie L.
McKenzie Thomas
Robinson Binta
SmithKline Beecham p.l.c.
LandOfFree
Hydroxyethylene compounds with Asp2 inhibitory activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxyethylene compounds with Asp2 inhibitory activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxyethylene compounds with Asp2 inhibitory activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3776095